Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction.

Author: Wenyu FU ¹ ; Yujianan CHEN ¹ ; Kaidi WANG ¹ ; Aubryanna HETTINGHOUSE ¹ ; Wenhuo HU ² ; Jing-Quan WANG ³ ; Zi-Ning LEI ³ ; Zhe-Sheng CHEN ³ ; Kenneth A STAPLEFORD ⁴ ; Chuan-Ju LIU ⁵
Author Information

1. Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York, NY, 10003, USA.
2. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
3. Department of Pharmaceutical Science, College of Pharmacy and Health Sciences, St. John's University, New York, NY, 11439, USA.
4. Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA. Kenneth.Stapleford@nyulangone.org.
5. Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York, NY, 10003, USA. chuanju.liu@nyumc.org.
Publication Type:Comment
MeSH: Angiotensin-Converting Enzyme 2; COVID-19; Drug Repositioning; Enzyme-Linked Immunosorbent Assay; Humans; Pharmaceutical Preparations; SARS-CoV-2
From: Protein & Cell 2021;12(7):586-591
CountryChina
Language:English